Low-Dose Urokinase in Major Pulmonary Embolism

Prevention of Clot Formation in Cat Retinal Vein by Systemic and Subconjunctival Urokinase

“…This is due to the urokinase-clot affinity and to the good penetration properties of the pro¬ tease. [16][17] We are not aware of any experimen¬ tal or clinical studies in which retinal vein occlusion is treated with a fibri¬ nolytic agent so soon after the throm¬ botic event. The unsatisfactory results obtained in studies in which the thrombolytic agent was introduced with considerable delay, either by the intravenous8 or the subconjunctival route,9 could be due to the thrombus being no longer susceptible to lysis, and also to the irreversible ischemie damage that preceded treatment.…”

Interventional Aspects of Chest Radiology

“…81 Local urokinase infusion, on the other hand, has been reported to enhance clot lysis significantly and to aid dramatically in resolving shock secondary to invasive emboli. 82 Some contend that local therapy is more effective than systemic administration owing to the action of alpha-2-macroglobulin inhibitors of urokinase, which reach the system circulation. 82 Whatever its mechanism of action, there is certainly enough evidence to recommend continuation of clinical trials for regional thrombolytic infusion.…”

“…82 Some contend that local therapy is more effective than systemic administration owing to the action of alpha-2-macroglobulin inhibitors of urokinase, which reach the system circulation. 82 Whatever its mechanism of action, there is certainly enough evidence to recommend continuation of clinical trials for regional thrombolytic infusion. 83 A bolus of urokinase into the main pulmonary artery that is compromised by clot may be the most beneficial approach to the patient with embolism-induced shock.…”